Dyslipidemia and peripheral arterial disease
Indian Heart J. 2024 Jan 13:S0019-4832(24)00010-5. doi: 10.1016/j.ihj.2024.01.010. Online ahead of print.ABSTRACTPeripheral arterial disease (PAD) affects 12 % of adult population and is increasing globally and in India. Peripheral arterial disease when associated with atherosclerosis in two or more other arterial beds such as coronary artery disease (CAD), mesenteric/renal artery and cerebrovascular disease (CVD), is known as polyvascular disease. The Reduction of Atherothrombosis for Continued Health (REACH) registry reported that 1 out of 6 patients had multi-vascular bed involvement. Progression of PAD to critical limb...
Source: Indian Heart J - January 15, 2024 Category: Cardiology Authors: Ajay Yadav Vivek Sawant Varinder Singh Bedi Kanupriya Yadav Source Type: research
Managing dyslipidemia in solid organ transplant patients
Indian Heart J. 2024 Jan 8:S0019-4832(24)00004-X. doi: 10.1016/j.ihj.2024.01.004. Online ahead of print.ABSTRACTSolid organ transplant recipients face an increased risk of dyslipidemia, which contributes to cardiovascular complications. Commonly used drugs such as ciclosporin and tacrolimus can aggravate and cause dyslipidemia. Immunosuppressive drugs particularly ciclosporin and tacrolimus are also known to worsendyslipidemia in transplant recipients. Mammalian target of rapamycin (mTOR) inhibitors like sirolimus and everolimus also alter lipid metabolism. Lifestyle and dietary modifications should be encouraged. Careful ...
Source: Indian Heart J - January 10, 2024 Category: Cardiology Authors: Ashwani Mehta Source Type: research
Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study
ConclusionsOur results do not provide evidence to support the hypothesis that reducing LDL-C levels with statins, alirocumab, or ezetimibe effectively prevents the risk of developing RA. However, our study provides valuable insights into the assessment of lipid-lowering agents in RA, which can enhance our understanding of the condition and assist in clinical practice by aiding in the determination and monitoring of RA status to clinical response.Key Points• Common lipid-lowering drugs such as statins, alirocumab, or evolocumab may not effectively prevent the development of rheumatoid arthritis.• This study provides clu...
Source: Clinical Rheumatology - January 10, 2024 Category: Rheumatology Source Type: research
Role of PCSK9 inhibitors in the management of dyslipidaemia
Indian Heart J. 2024 Jan 7:S0019-4832(23)00480-7. doi: 10.1016/j.ihj.2023.12.011. Online ahead of print.ABSTRACTProprotein convertase subtilisin kexin9 (PCSK9) inhibitors are novel agents that lower LDL cholesterol and reduce cardio-vascular event rate. Being expensive, these agents are reserved for those with high risk or very high risk of CV events and with suboptimal response to statins and ezetimibe, with or without bempedoic acid or those intolerant to statins.PMID:38195006 | DOI:10.1016/j.ihj.2023.12.011 (Source: Indian Heart J)
Source: Indian Heart J - January 9, 2024 Category: Cardiology Authors: Tiny Nair Source Type: research
Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study
CONCLUSION: In Swiss clinical practice, evolocumab was mainly prescribed to patients with very high cardiovascular risk, who had very high LDL-C levels. Most patients continued to use evolocumab throughout the study period. In these patients, LDL-C was reduced by >50% within 3 months and LDL-C reductions were maintained over time. Guideline-recommended LDL-C goals for this very high-risk cohort were more frequently attained in patients receiving a combination of statin and/or ezetimibe and evolocumab.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02770131.PMID:38183273 | PMC:PMC10771737 | DOI:10.1177/175394472312...
Source: Adv Data - January 6, 2024 Category: Epidemiology Authors: Isabella Sudano Stephan Kr ähenbühl Fran çois Mach Anne Anstett Nafeesa Dhalwani Ian Bridges Mahendra Sibartie Kausik K Ray Source Type: research
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
CONCLUSION: Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.PMID:38173371 | DOI:10.4093/dmj.2022.0402 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - January 4, 2024 Category: Endocrinology Authors: Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim Source Type: research
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
CONCLUSION: Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.PMID:38173371 | DOI:10.4093/dmj.2022.0402 (Source: Atherosclerosis)
Source: Atherosclerosis - January 4, 2024 Category: Cardiology Authors: Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim Source Type: research
Bempedoic acid, a new cholesterol-lowering agent
Ned Tijdschr Geneeskd. 2023 Nov 23;167:D7982.ABSTRACTStatins have been de cornerstone for the treatment of hyperlipidaemia for decades now. More recently the introduction of the PCSK9 inhibitors, inclisiran and even more recently bempedoic acid have given us new options for the treatment of hyperlipidaemia. Bempedoic acid is a prodrug which is metabolized in the liver and not in the peripheral tissues like muscles, this means that myalgia does not occur as a side effect. Its effect on the cholesterol synthesis occurs earlier in the chain of events than that of statins which work primarily via HMGcoA reductase. Other than t...
Source: Atherosclerosis - January 4, 2024 Category: Cardiology Authors: Andrew Oostindjer Jeanine E Roeters van Lennep Source Type: research
Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes
CONCLUSION: Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C-lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.PMID:38175670 | DOI:10.1210/clinem/dgad714 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 4, 2024 Category: Endocrinology Authors: So Young Park Ji Eun Jun In-Kyung Jeong Kyu Jeung Ahn Ho Yeon Chung You-Cheol Hwang Source Type: research
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
CONCLUSION: Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.PMID:38173371 | DOI:10.4093/dmj.2022.0402 (Source: Diabetes and Metabolism Journal)
Source: Diabetes and Metabolism Journal - January 4, 2024 Category: Endocrinology Authors: Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim Source Type: research
Comparative Efficacy of Rosuvastatin Monotherapy and Rosuvastatin/Ezetimibe Combination Therapy on Insulin Sensitivity and Vascular Inflammatory Response in Patients with Type 2 Diabetes Mellitus
CONCLUSION: Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin monotherapy, it had no additional effects on insulin sensitivity and vascular inflammatory response. Further studies are needed on the effect of long-term treatment with ezetimibe on insulin sensitivity and vascular inflammatory response.PMID:38173371 | DOI:10.4093/dmj.2022.0402 (Source: Atherosclerosis)
Source: Atherosclerosis - January 4, 2024 Category: Cardiology Authors: Ji Hye Han Kyong Hye Joung Jun Choul Lee Ok Soon Kim Sorim Choung Ji Min Kim Yea Eun Kang Hyon-Seung Yi Ju Hee Lee Bon Jeong Ku Hyun Jin Kim Source Type: research
Bempedoic acid, a new cholesterol-lowering agent
Ned Tijdschr Geneeskd. 2023 Nov 23;167:D7982.ABSTRACTStatins have been de cornerstone for the treatment of hyperlipidaemia for decades now. More recently the introduction of the PCSK9 inhibitors, inclisiran and even more recently bempedoic acid have given us new options for the treatment of hyperlipidaemia. Bempedoic acid is a prodrug which is metabolized in the liver and not in the peripheral tissues like muscles, this means that myalgia does not occur as a side effect. Its effect on the cholesterol synthesis occurs earlier in the chain of events than that of statins which work primarily via HMGcoA reductase. Other than t...
Source: Atherosclerosis - January 4, 2024 Category: Cardiology Authors: Andrew Oostindjer Jeanine E Roeters van Lennep Source Type: research
Comparison of the Efficacy of Ezetimibe Combination Therapy and High-Intensity Statin Monotherapy in Type 2 Diabetes
CONCLUSION: Adding ezetimibe to a moderate-intensity statin in patients with type 2 diabetes has a greater LDL-C-lowering effect and greater primary prevention of composite outcomes than that of high-intensity statin monotherapy.PMID:38175670 | DOI:10.1210/clinem/dgad714 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - January 4, 2024 Category: Endocrinology Authors: So Young Park Ji Eun Jun In-Kyung Jeong Kyu Jeung Ahn Ho Yeon Chung You-Cheol Hwang Source Type: research
